• Ibrexafungerp (MK 3118): Applied Workflows in Antifungal Res

  2026-06-19

  Ibrexafungerp (MK 3118) stands out for robust antifungal activity even in acidic conditions, overcoming key limitations of standard therapies. This article translates breakthrough reference findings into actionable protocols and troubleshooting tips for both in vitro and in vivo Candida research.

• Cy5 maleimide (non-sulfonated): Technical Guide for Protein

  2026-06-18

  Cy5 maleimide (non-sulfonated) enables site-specific fluorescent labeling of cysteine-containing biomolecules, making it valuable for researchers needing high-contrast visualization in protein tracking, imaging, and assay development. Its mono-reactive, thiol-selective chemistry and strong spectral properties suit diverse fluorescence applications, but its low aqueous solubility requires careful handling; it is not suitable for workflows demanding direct water dissolution or labeling of proteins lacking accessible thiol groups.

• In Vitro Antibacterial Spectrum of Leucomycin: Insights from

  2026-06-18

  This article examines the 1962 study by Iwata and Akiba, which systematically evaluated the in vitro antibacterial activity of leucomycin (kitasamycin) and its A1 fraction, including effects on erythromycin-resistant pathogens. The study's rigorous methodology and findings remain relevant for translational inhibition studies and resistance mechanism research.

• Commensal-Derived Exopolysaccharide Regulates Obesity via Im

  2026-06-17

  This study uncovers a specific exopolysaccharide from the human commensal Clostridium immunis that protects against obesity by modulating host immunometabolism. The findings highlight a defined bacterial molecule and its phosphocholine motif as key regulators of adipose tissue energy expenditure, offering insight into microbiome-driven metabolic control with translational potential.

• Gastrin I (human): Mechanisms and Strategy for Translational

  2026-06-17

  This article explores the mechanistic basis and translational potential of Gastrin I (human) in gastrointestinal research, emphasizing its application in advanced stem cell-derived organoid systems. It integrates primary literature, highlights protocol nuances, and provides strategic guidance for researchers aiming to leverage Gastrin I for both mechanistic insight and preclinical innovation, referencing both APExBIO’s high-purity peptide and recent organoid breakthroughs.

• CCG-1423: Potent RhoA Inhibitor for Pathway Dissection

  2026-06-16

  CCG-1423 is a high-purity RhoA inhibitor that selectively disrupts MRTF-A/importin α/β1 interactions, enabling precise investigation of RhoA transcriptional signaling in cancer and virology research. Its unique mechanism facilitates reproducible results in apoptosis and cellular proliferation assays.

• TG003 Cdc2-like Kinase Inhibitor: Workflows for Splicing Mod

  2026-06-16

  TG003, a potent Cdc2-like kinase inhibitor from APExBIO, stands at the forefront of alternative splicing research and platinum resistance studies. This guide translates recent mechanistic insights into actionable protocols, troubleshooting strategies, and advanced applications for pre-mRNA splicing and exon-skipping therapy.

• Carvacrol as a Redox-Active Probe: Beyond TRP Channel Modula

  2026-06-15

  Explore Carvacrol (5-isopropyl-2-methylphenol) as a precision redox probe for dissecting cell signaling and apoptosis. This article uniquely connects redox sensing, ion channel selectivity, and advanced protocol design for cell cycle and antioxidant research.

• KU-55933: ATM Kinase Inhibitor Impact on Cancer Metabolism

  2026-06-15

  Explore how KU-55933, a potent ATM kinase inhibitor, uniquely connects DNA damage signaling to cancer cell metabolism. This article unpacks the interplay between ATM inhibition, metabolic stress, and cell cycle arrest, offering practical protocol guidance for advanced cancer research.

• Alda 1: ALDH2 Activator for Cardiac Regeneration Research

  2026-06-14

  Alda 1, a potent ALDH2 activator from APExBIO, redefines experimental approaches in cardiac regeneration and aldehyde detoxification. This guide translates new mechanistic insights and protocol strategies into actionable workflows for ischemia and radiation-induced dermatitis models.

• Toremifene in Prostate Cancer: Beyond Estrogen Receptor Modu

  2026-06-13

  Explore how Toremifene, a selective estrogen-receptor modulator, uniquely advances prostate cancer research by bridging estrogen signaling and calcium pathway cross-talk. This article delivers a nuanced analysis of mechanistic insights and experimental strategies distinct from standard SERM workflows.

• Cycloastragenol Mitigates Osteoclast Activity in Steroid-Ind

  2026-06-12

  This study demonstrates that cycloastragenol prevents bone loss in a rat model of glucocorticoid-induced osteonecrosis of the femoral head by directly inhibiting osteoclast activity. The findings provide mechanistic insight into osteonecrosis pathogenesis and highlight cycloastragenol as a potential candidate for hip preservation strategies.

• Losartan Hydrogel Remodels Tumor Microenvironment to Boost I

  2026-06-12

  Hou et al. (2024) present a nanocomposite hydrogel integrating losartan and oxaliplatin that remodels the post-chemotherapy tumor mechanical microenvironment, enhancing chemo-immunotherapy response. Their approach demonstrates that targeting extracellular matrix stiffness can overcome resistance to immune checkpoint blockade, offering a new mechanistic rationale for neoadjuvant strategies.

• Metal-Chelating l-Phe Nanostructures Enhance Tumor Immunothe

  2026-06-11

  This study introduces metal-ion-chelating l-phenylalanine nanostructures as a strategy to remodel the immunosuppressive tumor microenvironment, thereby boosting the efficacy of immune checkpoint blockade in breast cancer. By leveraging ion channel modulation and dendritic cell activation, the approach offers a mechanistically distinct avenue for enhancing antitumor immune responses.

• LncRNA FAISL Blocks Calpain 2-Driven FAK Degradation in TNBC

  2026-06-11

  This study reveals how the lncRNA FAISL promotes triple negative breast cancer (TNBC) progression by inhibiting calpain 2-mediated proteolysis of FAK, stabilizing FAK protein and enhancing tumor cell survival and metastasis. The findings provide mechanistic clarity on FAK regulation in TNBC and suggest new avenues for targeted intervention.

450 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page